Aktieanalys

Össur: Incremental positive shifts in 2024 - ABG

ABG Sundal Collier Publicerad: 29 Jan 07:12

Q4e: Tuesday, 30 January at 8:00 CET
Healthy 2024 with 6% organic growth and solid margin expansion
Fair value reiterated at DKK 26-40

Q4 Tuesday 30 Jan 08:00, CC 09:00 CET

We are looking for Ossur to report Q4 sales of USD 217.7m (+15% reported growth), some 5% above company-collected Consensus at USD 207.3m. We are inline with consensus on organic growth (~6%), which leaves our higher estimate driven by lower-quality M&A and FX assumptions. We are looking for EBITDA pre-items of USD 44.3m, +6% vs. consensus, likely due to the higher top-line. We assume a modest slowing of growth in the key Prosthetics business of 8% organically (12% in Q3), which still assumes healthy market share gains.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/ossur/Equity-research/2024/1/ossur---incremental-positive-shifts-in-2024/

Nyheter om Embla Medical

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!